Cognitive neuroscientist conducting research in disorders of compulsive consumption - Gut Hormones in Addiction (GHADD). Much of this research is early phase translational experimental medicine - mapping the profile and potential efficacy of medications to modulate brain and behavioural markers in these disorders. Developing key methodologies that particularly exploit cognitive, reward and implicit motivational processes in these disorders - targets for future medication development. Valuable experience working in the pharma industry on early phase translational experimental medicine studies as a cognitive neuroscientist. Based at the Neuropsychopharmacology Unit, Division of Brain Sciences.
et al., 2019, Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and poly-substance dependent individuals, European Journal of Neuroscience, Vol:50, ISSN:0953-816X, Pages:2311-2321
et al., 2019, Cannabis‐dependent adolescents show differences in global reward‐associated network topology: A functional connectomics approach, Addiction Biology, ISSN:1355-6215
et al., 2018, The neural substrate of reward anticipation in health: a meta-analysis of fMRI findings in the M=monetary incentive delay task, Neuropsychology Review, Vol:28, ISSN:1040-7308, Pages:496-506
et al., 2017, Shared and divergent neural reactivity to non-drug operant response outcomes in current smokers and ex-smokers., Brain Research, Vol:1680, ISSN:0006-8993, Pages:54-61
et al., 2017, Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype, Neuropsychopharmacology, Vol:41, ISSN:0893-133X, Pages:2647-2657